Literature DB >> 24559288

The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.

Michael J Satlin1, Rosemary Soave, Alexandra C Racanelli, Tsiporah B Shore, Koen van Besien, Stephen G Jenkins, Thomas J Walsh.   

Abstract

Abstract As antimicrobial resistance increases, understanding the current epidemiology of bloodstream infections (BSIs) in hematopoietic stem cell transplant (HSCT) recipients is essential to guide empirical antimicrobial therapy. We therefore reviewed microbial etiologies, timing and outcomes of BSIs in patients who were transplanted from September 2007 to December 2011. Vancomycin-resistant enterococci (VRE) were the most common pathogens in allogeneic HSCT recipients and the fourth most common after autologous transplant. VRE did not cause any of 101 BSIs in neutropenic patients who were not receiving antibacterials, but caused 32 (55%) of 58 BSIs in neutropenic patients receiving a broad-spectrum β-lactam agent (p < 0.001). Rates of septic shock and 7-day mortality were 5% and 0% for streptococcal bacteremia, 12% and 18% for VRE bacteremia, and 20% and 14% for Gram-negative bacteremia. In conclusion, VRE bacteremia was the most common BSI in allogeneic HSCT recipients, occurred primarily in neutropenic patients receiving broad-spectrum β-lactams and was associated with poor outcomes.

Entities:  

Keywords:  Vancomycin-resistant enterococci; bloodstream infections; hematopoietic stem cell transplant recipients

Mesh:

Substances:

Year:  2014        PMID: 24559288      PMCID: PMC4316723          DOI: 10.3109/10428194.2014.896007

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  31 in total

1.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.

Authors:  Anand Kumar; Daniel Roberts; Kenneth E Wood; Bruce Light; Joseph E Parrillo; Satendra Sharma; Robert Suppes; Daniel Feinstein; Sergio Zanotti; Leo Taiberg; David Gurka; Aseem Kumar; Mary Cheang
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

2.  Heat and chemical resistance of enterococci.

Authors:  C R Bradley; A P Fraise
Journal:  J Hosp Infect       Date:  1996-11       Impact factor: 3.926

3.  Rhabdomyolysis during therapy with daptomycin.

Authors:  Stella Papadopoulos; Amanda M Ball; Susanne E Liewer; Craig A Martin; P Shane Winstead; Brian S Murphy
Journal:  Clin Infect Dis       Date:  2006-05-10       Impact factor: 9.079

4.  Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.

Authors:  Branimir Jaksic; Giovanni Martinelli; Jaime Perez-Oteyza; Charlotte S Hartman; Linda B Leonard; Kenneth J Tack
Journal:  Clin Infect Dis       Date:  2006-01-25       Impact factor: 9.079

5.  Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients.

Authors:  N G Almyroudis; A Fuller; A Jakubowski; K Sepkowitz; D Jaffe; T N Small; T E Kiehn; E Pamer; G A Papanicolaou
Journal:  Transpl Infect Dis       Date:  2005-03       Impact factor: 2.228

6.  Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course.

Authors:  R Avery; M Kalaycio; B Pohlman; R Sobecks; E Kuczkowski; S Andresen; S Mossad; J Shamp; J Curtis; J Kosar; K Sands; M Serafin; B Bolwell
Journal:  Bone Marrow Transplant       Date:  2005-03       Impact factor: 5.483

7.  A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.

Authors:  P A Pizzo; J W Hathorn; J Hiemenz; M Browne; J Commers; D Cotton; J Gress; D Longo; D Marshall; J McKnight
Journal:  N Engl J Med       Date:  1986-08-28       Impact factor: 91.245

8.  A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies.

Authors:  M J Leyland; K F Bayston; J Cohen; R Warren; A C Newland; A J Bint; C Cefai; D G White; S A Murray; D Bareford
Journal:  J Antimicrob Chemother       Date:  1992-12       Impact factor: 5.790

9.  Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality.

Authors:  D D Poutsiaka; L L Price; A Ucuzian; G W Chan; K B Miller; D R Snydman
Journal:  Bone Marrow Transplant       Date:  2007-04-30       Impact factor: 5.483

10.  Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant.

Authors:  David M Weinstock; Mary Conlon; Christine Iovino; Tanya Aubrey; Carlota Gudiol; Elyn Riedel; James W Young; Timothy E Kiehn; Gianna Zuccotti
Journal:  Biol Blood Marrow Transplant       Date:  2007-03-23       Impact factor: 5.742

View more
  12 in total

1.  Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Michael J Satlin; Santosh Vardhana; Rosemary Soave; Tsiporah B Shore; Tomer M Mark; Samantha E Jacobs; Thomas J Walsh; Usama Gergis
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-03       Impact factor: 5.742

Review 2.  Vancomycin-resistant enterococci (VRE): a reason to isolate?

Authors:  Maria J G T Vehreschild; Miriam Haverkamp; Lena M Biehl; Sebastian Lemmen; Gerd Fätkenheuer
Journal:  Infection       Date:  2018-09-03       Impact factor: 3.553

3.  Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy.

Authors:  Andreas F Widmer; Winfried V Kern; Jan A Roth; Markus Dettenkofer; Tim Goetting; Hartmut Bertz; Christian Theilacker
Journal:  Infection       Date:  2019-06-11       Impact factor: 3.553

Review 4.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

5.  Impact of Empiric Treatment for Vancomycin-Resistant Enterococcus in Colonized Patients Early after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Mini Kamboj; Nina Cohen; Yao-Ting Huang; Marina Kerpelev; Ann Jakubowski; Kent A Sepkowitz; Genovefa A Papanicolaou; Susan K Seo
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-15       Impact factor: 5.742

Review 6.  Laboratory Diagnosis of Infections in Cancer Patients: Challenges and Opportunities.

Authors:  N Esther Babady
Journal:  J Clin Microbiol       Date:  2016-06-08       Impact factor: 5.948

7.  Incidence, clinical characteristics, and outcomes of nosocomial Enterococcus spp. bloodstream infections in a tertiary-care hospital in Beijing, China: a four-year retrospective study.

Authors:  Yangyang Zhang; Mingmei Du; Yan Chang; Liang-An Chen; Qing Zhang
Journal:  Antimicrob Resist Infect Control       Date:  2017-07-04       Impact factor: 4.887

8.  Infectious Complications After Umbilical Cord Blood Transplantation for Hematological Malignancy.

Authors:  Kathleen A Linder; Philip J McDonald; Carol A Kauffman; Sanjay G Revankar; Pranatharthi H Chandrasekar; Marisa H Miceli
Journal:  Open Forum Infect Dis       Date:  2019-02-22       Impact factor: 3.835

Review 9.  Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention.

Authors:  Esther Benamu; Stanley Deresinski
Journal:  F1000Res       Date:  2018-01-02

10.  Epidemiology, treatment and outcomes of bloodstream infection due to vancomycin-resistant enterococci in cancer patients in a vanB endemic setting.

Authors:  Ouli Xie; Monica A Slavin; Benjamin W Teh; Ashish Bajel; Abby P Douglas; Leon J Worth
Journal:  BMC Infect Dis       Date:  2020-03-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.